CPT1A Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P50416 |
---|---|
Clone Names | 3083112 |
Gene ID | 1374 |
---|---|
Other Names | Carnitine O-palmitoyltransferase 1, liver isoform, CPT1-L, Carnitine O-palmitoyltransferase I, liver isoform, CPT I, CPTI-L, Carnitine palmitoyltransferase 1A, CPT1A, CPT1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2524b was selected from the C-term region of human CPT1A . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CPT1A (HGNC:2328) |
---|---|
Synonyms | CPT1 |
Function | Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion (PubMed:11350182, PubMed:14517221, PubMed:16651524, PubMed:9691089). Also possesses a lysine succinyltransferase activity that can regulate enzymatic activity of substrate proteins such as ENO1 and metabolism independent of its classical carnitine O-palmitoyltransferase activity (PubMed:29425493). Plays an important role in hepatic triglyceride metabolism (By similarity). Also plays a role in inducible regulatory T-cell (iTreg) differentiation once activated by butyryl-CoA that antagonizes malonyl- CoA-mediated CPT1A repression (By similarity). Sustains the IFN-I response by recruiting ZDHCC4 to palmitoylate MAVS at the mitochondria leading to MAVS stabilization and activation (PubMed:38016475). Promotes ROS-induced oxidative stress in liver injury via modulation of NFE2L2 and NLRP3-mediated signaling pathways (By similarity). |
Cellular Location | Mitochondrion outer membrane; Multi-pass membrane protein |
Tissue Location | Strong expression in kidney and heart, and lower in liver and skeletal muscle |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The mitochondrial oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase I (which is located in the outer membrane and is detergent-labile) and carnitine palmitoyltransferase II (which is located in the inner membrane and is detergent-stable), together with a carnitine-acylcarnitine translocase. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation.
References
Rasmussen, B.B., et al., J. Clin. Invest. 110(11):1687-1693 (2002).Ogawa, E., et al., J. Hum. Genet. 47(7):342-347 (2002).Cook, G.A., et al., Am. J. Med. Sci. 318(1):43-48 (1999).IJlst, L., et al., J. Clin. Invest. 102(3):527-531 (1998).Britton, C.H., et al., Genomics 40(1):209-211 (1997).

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.